full timeline
Giredestrant breast cancer drug development
The FDA has cleared a new targeted pill for patients with metastatic hormone-positive breast cancer that has stopped responding to initial treatments.
Follow Giredestrant breast cancer drug development in the Factlen app and get an alert when there is news. Get the app
Share this story
Latest report
FDA Approves Roche's Oral Therapy Giredestrant for Advanced Breast Cancer
The FDA has cleared a new targeted pill for patients with metastatic hormone-positive breast cancer that has stopped responding to initial treatments. The drug, combined with everolimus, specifically targets tumors that have developed a resistance-driving genetic mutation.
- The FDA approved Roche's oral SERD giredestrant (Wilserdly) in combination with everolimus for advanced ESR1-mutated breast cancer.
- The combination reduced the risk of disease progression or death by 62 percent compared to standard hormone therapy in the Phase 3 evERA trial.
- The FDA also authorized a liquid biopsy blood test to detect the ESR1 mutation, which develops in up to 40 percent of metastatic cases.
- A separate FDA decision on using giredestrant for early-stage breast cancer is expected by November 30, 2026.
The U.S. Food and Drug Administration has approved a new oral targeted therapy for patients with advanced breast cancer that has stopped responding to standard hormone treatments. The decision clears Roche’s giredestrant, marketed as Wilserdly, for use alongside the targeted drug everolimus.[1][2]
The approval specifically covers adults with estrogen receptor-positive, HER2-negative metastatic breast cancer who carry a specific genetic mutation known as ESR1. This mutation frequently develops after initial rounds of treatment and allows tumors to evade traditional estrogen-blocking drugs.[3][4]
By combining a next-generation estrogen degrader with an existing growth-pathway inhibitor, the regimen offers a new fallback for patients whose disease has progressed. The FDA reached its decision a month ahead of its target action date, reflecting the urgent need for effective therapies in this setting.[3][4]
Overcoming treatment resistance
Hormone receptor-positive breast cancer accounts for roughly 70 percent of all diagnoses, and standard care typically begins with drugs that block estrogen production or its ability to bind to cells. However, when the disease spreads, the cancer often adapts.[2]
Up to 40 percent of patients with metastatic hormone-positive breast cancer eventually develop an ESR1 mutation. This genetic alteration changes the shape of the estrogen receptor, locking it in an active state so the tumor can continue growing even without circulating estrogen.[2][4]
Giredestrant belongs to a newer class of drugs called selective estrogen receptor degraders, or SERDs. Instead of merely blocking the receptor, the daily pill binds to the mutated protein and flags it for destruction by the cell’s own waste-disposal machinery.[2][3]
The clinical evidence
The FDA based its approval on the Phase 3 evERA clinical trial, which enrolled patients whose cancer had already progressed after treatment with a CDK4/6 inhibitor—the current standard first-line therapy.[2][3]
Participants were randomly assigned to receive either giredestrant or their physician’s choice of standard hormone therapy, with both groups also taking everolimus. Everolimus works by inhibiting mTOR, a separate protein pathway that cancer cells use to survive and multiply.[1][2]
The results demonstrated a clear advantage for the new combination in the mutation-positive group. Patients taking giredestrant and everolimus lived a median of 10 months without their cancer growing, compared to 5.5 months for those on standard hormone therapy.[3]
Overall, the dual-drug regimen reduced the risk of disease progression or death by 62 percent in patients with the ESR1 mutation. Roche noted that this makes Wilserdly the first oral SERD combination to significantly outperform standard care in a head-to-head trial following CDK4/6 inhibitor treatment.[2][3]
Practical steps for patients
For patients currently navigating metastatic breast cancer, this approval changes the testing landscape. Because the drug is only cleared for tumors with the ESR1 mutation, identifying that genetic signature is now a critical step in treatment planning.[1][4]
Alongside the drug, the FDA authorized the FoundationOne Liquid CDx assay as a companion diagnostic test. This liquid biopsy requires only a standard blood draw, allowing oncologists to detect the mutation through circulating tumor DNA without needing a surgical tissue biopsy.[1]
The liquid biopsy approach is particularly valuable for patients with metastatic disease, where tumors may be located in the bones, liver, or lungs. Extracting tissue from these sites is invasive, painful, and sometimes medically risky.[1][2]
Patients whose disease is currently stable on their first-line therapies do not need to change their regimen. However, those experiencing disease progression should ask their oncology team whether a liquid biopsy is appropriate to check for emerging resistance mutations.[2][4]
The combination is taken entirely as oral pills, allowing patients to manage their treatment at home. This spares them the monthly intramuscular injections required by older estrogen-degrading drugs, reducing clinic visits and injection-site pain.[2][3]
A crowded therapeutic class
Giredestrant is not the first drug of its kind to reach the market, but it enters a rapidly evolving field. It is the fourth oral SERD approved by the FDA, joining Menarini’s elacestrant, Eli Lilly’s imlunestrant, and AstraZeneca’s camizestrant.[3][4]
Each of these drugs targets the estrogen receptor, but they differ slightly in their clinical development and approved combinations. Wilserdly is uniquely approved for use specifically alongside everolimus in the second-line setting, giving oncologists another tool to tailor therapy.[3][4]
The rapid succession of approvals reflects a broader shift in oncology toward precision medicine. Rather than treating all hormone-positive breast cancers identically, doctors are increasingly matching specific targeted drugs to the exact genetic mutations driving a patient’s tumor at that moment.[2][4]
Looking toward early-stage disease
While the current approval focuses on advanced cancer, the drug’s biggest impact may lie ahead. The FDA is currently reviewing a separate application for giredestrant as an adjuvant, or post-surgical, treatment for early-stage breast cancer.[2][3]
That application rests on the Phase 3 lidERA trial, which tested the drug in patients with stage I to III disease who face an intermediate to high risk of recurrence.[2]
The agency is expected to issue a decision on the early-stage indication by November 30, 2026. If cleared, giredestrant would become the first new adjuvant endocrine therapy approved in more than two decades, potentially altering standard care for thousands of newly diagnosed patients.[2][3]
Managing side effects
Like all targeted therapies, the new combination carries a specific side-effect profile that requires monitoring. Everolimus is known to cause mouth sores, fatigue, and elevated blood sugar, which patients must manage carefully with their care team.[1]
Giredestrant’s primary side effects align with other estrogen-blocking drugs, including joint pain, hot flashes, and nausea. Because the regimen suppresses estrogen profoundly, it can also accelerate bone thinning, making regular bone density scans an important part of long-term care.[1][2]
Regular blood tests are also required to monitor liver function and blood counts, as the dual-pathway blockade can occasionally suppress bone marrow activity. Despite these requirements, clinical trial data indicates that most patients tolerate the combination well enough to remain on therapy.[1][2]
Oncologists emphasize that while the regimen extends the time before the disease progresses, it is not a cure for metastatic cancer. The goal remains to control the tumor for as long as possible while maintaining the patient's quality of life.[2][4]
The evolving standard of care
The approval underscores the importance of continuous monitoring in metastatic disease. Tumors are dynamic, and the genetic mutations that drive them can change in response to the evolutionary pressure of treatment.[2][4]
Sources
- [1]FDA — FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer Read on FDA →
- [2]Roche — FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer Read on Roche →
- [3]Fierce Pharma — Roche's next big breast cancer drug, Wilserdly, secures FDA approval as 4th oral SERD Read on Fierce Pharma →
- [4]Endpoints News — FDA approves Roche's oral SERD Wilserdly with everolimus in ESR1-mutated advanced breast cancer, a month ahead of its Read on Endpoints News →
What to watch
- A separate FDA decision on using giredestrant for early-stage breast cancer is expected by November 30.
Charts, maps and images
Timeline
November 2026
FDA Approves Roche's Oral Therapy Giredestrant for Advanced Breast Cancer
October 2026
Phase 3 Trial Shows Oral Giredestrant Combination Significantly Slows Advanced Breast Cancer Progression
How the story developed
The clinical pathway for giredestrant centered on finding alternatives for patients with estrogen receptor-positive, HER2-negative tumors that no longer respond to initial hormone therapies. Researchers focused on developing an oral regimen to replace traditional intravenous treatments, enabling patients to manage their disease at home and avoid frequent hospital visits.
On October 5, results from the phase 3 evERA trial demonstrated the efficacy of a dual-drug approach. The study evaluated the combination of oral giredestrant with everolimus in patients with advanced breast cancer.
The trial data showed that the oral drug combination cut the overall risk of disease progression by forty-four percent. The regimen proved highly effective as a pill-based alternative to standard therapies.
The combination was found to be especially effective in patients whose tumors had developed specific genetic characteristics. In patients with ESR1 gene mutations, the dual-drug approach reduced the risk of disease progression or death by sixty-two percent compared to standard hormone therapy.

